Enveric Biosciences Inc Stock

$0.32

2.89% yesterday

Nasdaq, Dec 23, 09:37 pm CET

ISIN

US29405E1091

Symbol

ENVB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Enveric Biosciences Inc Stock price

$0.31

-431.69 99.93% 5Y

Nasdaq, Closing price Mon, Dec 23 2024

-0.02 4.62%

ISIN

US29405E1091

Symbol

ENVB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$3.15m
Enterprise Value	$40.00k
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	0.71
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-8.84m
Free Cash Flow (TTM) Free Cash Flow	$-8.17m
Cash position	$3.11m
EPS (TTM) EPS	$-2.56
P/E forward	negative
Short interest	3.73%

As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.

Get Started for Free Today

Enveric Biosciences Inc Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast Enveric Biosciences Inc:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast Enveric Biosciences Inc:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Enveric Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.34 0.34	17% 17% -
Gross Profit	-0.34 -0.34	17% 17% -
- Selling and Administrative Expenses	5.06 5.06	51% 51% -
- Research and Development Expense	3.11 3.11	60% 60% -
EBITDA	-8.50 -8.50	54% 54% -
- Depreciation and Amortization	0.34 0.34	17% 17% -
EBIT (Operating Income) EBIT	-8.84 -8.84	53% 53% -
Net Profit	-9.86 -9.86	56% 56% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Enveric Biosciences Inc Stock News

Neutral

Business Wire

●

22 days ago

Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued two U.S. Patents, Nos. 12,133,856 (th...

Neutral

Business Wire

●

29 days ago

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogen small molecule therapeutics for the treatment of depression, anxiety, and other psychiatric disorders, today announced the completion of preclinical pharmacokinetic (“PK”) studies in rat and dog further supporting ...

Neutral

Business Wire

●

about one month ago

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the third quarter ended September 30, 2024. “The third...

More Enveric Biosciences Inc News

Company Profile

Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. The firm is testing natural compounds, starting with cannabinoids to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs. The company is headquartered in Naples, FL.

Head office	United States
CEO	Joseph Tucker
Employees	7
Founded	1994
Website	www.enveric.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now